Details for Patent: 11,311,532
✉ Email this page to a colleague
Which drugs does patent 11,311,532 protect, and when does it expire?
Patent 11,311,532 protects INGREZZA and is included in one NDA.
This patent has sixteen patent family members in thirteen countries.
Summary for Patent: 11,311,532
Title: | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Abstract: | Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate. |
Inventor(s): | Moore, Jr.; Richard Alexander (San Diego, CA), McClelland; Gregory A. (San Diego, CA), O'Brien; Christopher F. (Vashon, WA) |
Assignee: | Neurocrine Biosciences, Inc. (San Diego, CA) |
Application Number: | 17/074,383 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Dosage form; |
Recent additions to Drugs Protected by US Patent 11,311,532
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,311,532
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Try a Trial | ||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Try a Trial | ||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Try a Trial | |||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Try a Trial | |||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Try a Trial | ||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,311,532
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 112819 | ⤷ Try a Trial | |||
Australia | 2018335259 | ⤷ Try a Trial | |||
Brazil | 112020005373 | ⤷ Try a Trial | |||
Canada | 3076000 | ⤷ Try a Trial | |||
China | 111372567 | ⤷ Try a Trial | |||
Eurasian Patent Organization | 202090809 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |